{"id":"high-dose-intravenous-methotrexate","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"30-60","effect":"Mucositis"},{"rate":"30-50","effect":"Nausea and vomiting"},{"rate":"10-30","effect":"Hepatotoxicity"},{"rate":"5-20","effect":"Nephrotoxicity"},{"rate":"5-15","effect":"Neurotoxicity"},{"rate":"20-40","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methotrexate is a folate antagonist that inhibits dihydrofolate reductase, preventing the conversion of dihydrofolate to tetrahydrofolate, which is essential for one-carbon transfer reactions and nucleotide synthesis. At high doses administered intravenously, it achieves high intracellular concentrations that are particularly toxic to rapidly dividing cancer cells. High-dose regimens are often followed by leucovorin rescue to protect normal tissues from excessive toxicity.","oneSentence":"High-dose intravenous methotrexate inhibits dihydrofolate reductase, blocking DNA synthesis and cell division in rapidly proliferating cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:51.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (lymphomas, leukemias)"},{"name":"Osteosarcoma"},{"name":"Breast cancer"},{"name":"Head and neck cancers"}]},"trialDetails":[{"nctId":"NCT06252870","phase":"PHASE2","title":"Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-07-18","conditions":"Graft Versus Host Disease, Hematologic Malignancy","enrollment":82},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT07313878","phase":"NA","title":"Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Microscopy","status":"RECRUITING","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2025-11-19","conditions":"Acute Lymphoblastic Leukaemias (ALL), Long Term Follow-Up","enrollment":30},{"nctId":"NCT01046825","phase":"PHASE2, PHASE3","title":"Mature B-Cell Lymphoma And Leukemia Study III","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-09-09","conditions":"Mature B-Cell Lymphoma","enrollment":128},{"nctId":"NCT05698147","phase":"PHASE1, PHASE2","title":"Selinexor in Combination With MTX+Ritu to Treat R/R CNSL","status":"RECRUITING","sponsor":"Tong Chen, MD","startDate":"2023-08-03","conditions":"Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT05745714","phase":"PHASE1, PHASE2","title":"HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2025-10-01","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT07175415","phase":"PHASE1, PHASE2","title":"HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2026-10-01","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory","enrollment":42},{"nctId":"NCT05751044","phase":"PHASE1, PHASE2","title":"HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2025-10-01","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT06262438","phase":"PHASE2","title":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2024-02-06","conditions":"Acute Myeloid Leukemia in Children","enrollment":60},{"nctId":"NCT06973811","phase":"PHASE2","title":"ZR-MTX for PIOL Phase II Trial","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-05-10","conditions":"Primary Intraocular Lymphoma","enrollment":47},{"nctId":"NCT04737889","phase":"PHASE2","title":"Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2021-01-13","conditions":"Primary Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT01228331","phase":"PHASE2, PHASE3","title":"Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2010-10","conditions":"Leukemia","enrollment":745},{"nctId":"NCT05036577","phase":"PHASE1","title":"A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huashan Hospital","startDate":"2021-10-10","conditions":"Primary Central Nervous System Lymphoma","enrollment":15},{"nctId":"NCT06646211","phase":"PHASE2","title":"High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-01-01","conditions":"Primary Central Nervous System Lymphoma (PCNSL), Non Hodgkin Lymphoma (NHL)","enrollment":30},{"nctId":"NCT02393859","phase":"PHASE3","title":"Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-11-10","conditions":"Leukemia, Acute Lymphoblastic","enrollment":111},{"nctId":"NCT06336395","phase":"PHASE2","title":"Ma-Spore ALL 2020 Study","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2020-03-04","conditions":"B Lymphoblastic Leukemia","enrollment":500},{"nctId":"NCT02013167","phase":"PHASE3","title":"Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-01-03","conditions":"Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia","enrollment":405},{"nctId":"NCT03964259","phase":"PHASE1","title":"Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2019-10-02","conditions":"Lymphoma, Acute Lymphoblastic Leukemia, Pediatric Cancer","enrollment":10},{"nctId":"NCT06175702","phase":"","title":"Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2023-12-25","conditions":"Lymphoblastic Leukemia, Philadelphia-Positive ALL, Adult ALL","enrollment":150},{"nctId":"NCT00540995","phase":"PHASE1, PHASE2","title":"Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2007-06-11","conditions":"Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)","enrollment":25},{"nctId":"NCT04006561","phase":"","title":"Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-03-01","conditions":"Primary CNS Lymphoma, Brain Lymphoma","enrollment":36},{"nctId":"NCT03613181","phase":"PHASE3","title":"ANG1005 in Leptomeningeal Disease From Breast Cancer","status":"UNKNOWN","sponsor":"Angiochem Inc","startDate":"2023-12","conditions":"Leptomeningeal Carcinomatosis, Leptomeningeal Metastases, Brain Metastases","enrollment":150},{"nctId":"NCT02440464","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Multiple Myeloma","enrollment":57},{"nctId":"NCT05135858","phase":"PHASE1","title":"Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-09-15","conditions":"Primary Central Nervous System Lymphoma","enrollment":18},{"nctId":"NCT05578378","phase":"PHASE2, PHASE3","title":"Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-01-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":32},{"nctId":"NCT00482833","phase":"PHASE3","title":"Phase III Trial in Acute Promyelocytic Leukemia Patients","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2007-08","conditions":"Leukemia","enrollment":276},{"nctId":"NCT01773395","phase":"PHASE2","title":"GVAX vs. Placebo for MDS/AML After Allo HSCT","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-01-08","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":123},{"nctId":"NCT00634504","phase":"PHASE1","title":"Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze","status":"COMPLETED","sponsor":"BTG International Inc.","startDate":"2008-05","conditions":"Osteosarcoma, Leukemia, Lymphoma","enrollment":20},{"nctId":"NCT01176981","phase":"PHASE3","title":"Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2010-10","conditions":"Osteosarcoma","enrollment":6},{"nctId":"NCT05054426","phase":"PHASE3","title":"Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-10-08","conditions":"Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma","enrollment":488},{"nctId":"NCT01104025","phase":"PHASE2","title":"Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2010-04","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":31},{"nctId":"NCT00267865","phase":"PHASE2","title":"Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-09-14","conditions":"AIDS-Related-Primary Central Nervous System Lymphoma","enrollment":12},{"nctId":"NCT00632827","phase":"PHASE2","title":"Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2008-07-01","conditions":"Peripheral T-Cell Lymphoma","enrollment":21},{"nctId":"NCT04283955","phase":"","title":"A Retrospective Cohort Study: The Influence of MTHFR C677T and A1298C on the High-dose Methotrexate-Related Toxicities in Pediatric Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-03-01","conditions":"Pediatric NHL","enrollment":93},{"nctId":"NCT01953770","phase":"NA","title":"Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2008-02","conditions":"Childhood Acute Lymphoblastic Leukemia","enrollment":3000},{"nctId":"NCT02518750","phase":"PHASE2","title":"Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-11-23","conditions":"Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell","enrollment":3},{"nctId":"NCT00520130","phase":"PHASE1, PHASE2","title":"Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-10-30","conditions":"Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease","enrollment":92},{"nctId":"NCT00968253","phase":"PHASE1, PHASE2","title":"RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-11","conditions":"Leukemia, Acute Lymphocytic Leukemia","enrollment":24},{"nctId":"NCT00037102","phase":"PHASE4","title":"Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis","status":"COMPLETED","sponsor":"MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute","startDate":"2001-07","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT00037115","phase":"PHASE4","title":"Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.","status":"WITHDRAWN","sponsor":"MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute","startDate":"2002-05","conditions":"Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis","enrollment":""},{"nctId":"NCT03408223","phase":"NA","title":"Total Marrow and Lymphoid Irradiation and Chemotherapy for High-Risk Acute Leukemia","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2014-03","conditions":"Acute Leukemia","enrollment":100},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT03280979","phase":"PHASE2, PHASE3","title":"Rescue Regimen and High Dose Methotrexate in Management of Presistent Gestational Trophoplastic Neoplasia","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-10","conditions":"Gestational Trophoblastic Disease","enrollment":170},{"nctId":"NCT03123718","phase":"PHASE3","title":"High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL","status":"UNKNOWN","sponsor":"Chonnam National University Hospital","startDate":"2017-07-01","conditions":"DLBCL","enrollment":205},{"nctId":"NCT01181271","phase":"PHASE2","title":"Tandem Auto-Allo Transplant for Lymphoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-08","conditions":"Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma","enrollment":42},{"nctId":"NCT01991158","phase":"PHASE2","title":"GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-11","conditions":"Extranodal NK/T-cell Lymphoma, Nasal Type","enrollment":30},{"nctId":"NCT00635726","phase":"PHASE2","title":"Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer","status":"TERMINATED","sponsor":"Hellenic Oncology Research Group","startDate":"2008-02","conditions":"Bladder Cancer","enrollment":41},{"nctId":"NCT00298272","phase":"PHASE2","title":"Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Biogen","startDate":"2006-05","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT00038610","phase":"PHASE2","title":"Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2001-03","conditions":"Leukemia","enrollment":54},{"nctId":"NCT00673179","phase":"NA","title":"Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-05","conditions":"Osteosarcoma","enrollment":7},{"nctId":"NCT00513981","phase":"PHASE1","title":"High-Dose Methotrexate in Treating Young Patients With Solid Tumors","status":"COMPLETED","sponsor":"Children's Cancer and Leukaemia Group","startDate":"2007-03","conditions":"Brain and Central Nervous System Tumors, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":36},{"nctId":"NCT00230035","phase":"PHASE2","title":"Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"Systemic Lupus Erythematosus","enrollment":""},{"nctId":"NCT00787761","phase":"PHASE2","title":"Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2007-04","conditions":"Myeloproliferative Disorders, Kidney Cancer, Leukemia","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":87,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"High-dose intravenous methotrexate","genericName":"High-dose intravenous methotrexate","companyName":"Chonnam National University Hospital","companyId":"chonnam-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose intravenous methotrexate inhibits dihydrofolate reductase, blocking DNA synthesis and cell division in rapidly proliferating cells. Used for Hematologic malignancies (lymphomas, leukemias), Osteosarcoma, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}